Microparticle Hemostatic Agents for Endoscopic Conduit Patency
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current hemostatic agents used in endoscopic procedures often cause blockages in medical conduits during administration, limiting their effectiveness in stopping bleeding and wound dressing due to pressure constraints within the conduit.
Innovation Solution
Development of biocompatible and biodegradable polymer microparticles with a diameter of 100-350 µm, which can be administered through medical conduits with inner diameters of 1.0-3.5 mm at pressures of 0.5-2 bar without causing blockages, allowing for effective bleeding control and wound dressing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hemostatic agent is sprayed through medical conduit at high pressure to prevent blockage, then conduit blockage is reduced, but surgical site is damaged by excessive pressure
Solution Approach 1:
The patent changes the physical state of the hemostatic agent from liquid to microparticle form with specific size parameters (1-500 µm). This parameter change allows the agent to flow through the conduit at low pressure (0.5-2 bar) without causing blockages, while avoiding the tissue damage associated with high-pressure liquid injection. The microparticle size parameters are specifically optimized to pass through the conduit while maintaining flowability.
2Productivity
If pressure supplied to medical conduit is increased to solve blockage, then hemostatic agent delivery is improved, but bleeding site is affected by pressure increase
Solution Approach 1:
The invention transforms the delivery system by changing the physical parameters of the hemostatic agent into microparticles with optimized size distribution. This allows efficient delivery through the conduit at low pressure (0.5-2 bar), achieving high productivity without the harmful effects of pressure increase on the bleeding site.
Solution Approach 2:
The hemostatic agent is segmented into discrete microparticles rather than delivered as a continuous liquid stream. This segmentation allows the particles to navigate the conduit independently at low pressure, improving delivery efficiency while avoiding the集中 pressure effects that would disturb the bleeding site.
3Ease of operation
If hemostatic agent is delivered through narrow medical conduit, then minimally invasive approach is maintained, but conduit blockage occurs
Solution Approach 1:
The patent optimizes the microparticle size parameters (1-500 µm) to match the conduit dimensions, allowing the particles to pass through narrow conduits (including those with 1.2-3.5 mm inner diameter) without blockage. This maintains the minimally invasive approach while ensuring reliable conduit patency throughout the procedure.
Solution Approach 2:
The microparticles exhibit dynamic flow behavior that adapts to the conduit geometry, allowing them to navigate narrow passages effectively. The particles can deform and adjust their movement patterns to pass through the narrow conduit without causing blockages, maintaining both minimal invasiveness and conduit patency.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention provides administrable microparticles in vivo through a medical conduit, a composition comprising the same, and a manufacturing method therefor. The microparticles of the present invention have an advantage that a clogging phenomenon does not occur for an endoscopic administration through a spray apparatus.